The PARP inhibitor ABT-888 (Veliparib) showed a trend toward increased activity, with case reports and early-phase studies suggesting that tumors harboring homologous recombination repair deficiencies, particularly BRCA2 alterations, may be more susceptible; however, evidence in prostate cancer remains limited (31). This evidence concerns the gene BRCA2 and prostate carcinoma.